Sandford Kinne, DO
Family Medicine · Ormond Beach, FLNPI 1043328735
Payments from drug & device makers
Across 243 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$604
- AbbVie$602
- Pfizer$433
- Astellas Pharma US Inc$313
- Amgen$295
- Otsuka America Pharmaceutical, Inc.$275
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,500100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $604 |
| AbbVie(2 entities) | 31 | $602 |
| Pfizer | 24 | $433 |
| Astellas Pharma US Inc | 18 | $313 |
| Amgen(2 entities) | 17 | $295 |
| Otsuka America Pharmaceutical, Inc. | 11 | $275 |
| Lilly USA, LLC | 14 | $265 |
| Radius Health, Inc. | 9 | $247 |
| Abbott | 13 | $225 |
| Amarin Pharma, Inc. | 10 | $212 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $190 |
| Exact Sciences | 5 | $79 |
| AstraZeneca | 5 | $75 |
| Merck | 4 | $75 |
| Mylan Specialty L.p. | 3 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Boehringer Ingelheim | 3 | $54 |
| GSK | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Johnson & Johnson | 3 | $46 |
| Corcept Therapeutics | 2 | $41 |
| Almatica Pharma LLC | 1 | $32 |
| Medtronic | 2 | $31 |
| Bayer | 1 | $25 |
| Boston Scientific | 2 | $23 |
| Quidel Corporation | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Renalytix AI, Inc. | 1 | $16 |
| Abiomed | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,500 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 694 | $332,291 |
| OzempicSemaglutide | 140 | $162,690 |
| XareltoRivaroxaban | 109 | $85,453 |
| MounjaroTirzepatide | 66 | $74,901 |
| JardianceEmpagliflozin | 119 | $71,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $62,183 |
| JanuviaSitagliptin Phosphate | 91 | $52,471 |
| Repatha SureclickEvolocumab | 47 | $38,197 |
| TradjentaLinagliptin | 31 | $25,621 |
| EntrestoSacubitril/Valsartan | 44 | $23,965 |
| TrulicityDulaglutide | 26 | $23,843 |
| MyrbetriqMirabegron | 38 | $22,612 |
| LinzessLinaclotide | 33 | $19,608 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $17,068 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 117 | $13,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin, Retacrit | $433 | $342,850731 claims |
| Novo NordiskOzempic | $604 | $162,690140 claims |
| Lilly USA, LLCMounjaro, Trulicity | $265 | $98,74392 claims |
| Boehringer IngelheimJardiance, Tradjenta | $54 | $97,480150 claims |
| Johnson & JohnsonXarelto | $46 | $85,453109 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $49 | $79,25198 claims |
| MerckJanuvia | $75 | $52,47191 claims |
| AbbVieLinzess, Synthroid | $602 | $26,256119 claims |
| Astellas Pharma US IncMyrbetriq | $313 | $22,61238 claims |
| AstraZenecaFarxiga, Symbicort | $75 | $17,56231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ormond Beach
- Diego Torres IiOrmond Beach$8.3M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.